Lonza signs big pharma deal

- Last updated on GMT

Lonza has inked a deal with a big pharma that will see the Swiss-based CMO use its microreactor technology (MRT), which it claims can boost yield, cut changeover time and reduce solvent use.

The contract manufacturing organisation (CMO) launched its MRT service in 2003 and said that this latest contract would strengthen its position in the market.

Uwe Böhlke, head of Lonza exclusive synthesis, added: “The Lonza microcreactor offers state-of-the-art technology and assures quality robustness, easy cleaning and change-over procedures in a GMP environment. The Lonza reactor is capable of producing three tons of isolated materials within a campaign of a few weeks​.”

Related topics: Contract Manufacturing & Logistics

Related news

Follow us

Products

View more

Webinars